Merck Reports Results of Doravirine/Islatravir as Fixed Dose Combination in P-III Trials for the Treatment of HIV-1 Infection
Shots: The 2 P-III ILLUMINATE SWITCH A & B trials evaluate doravirine/islatravir (100/0.75mg, qd, PO) in a ratio (1:1) in 672 & 641 patients with […]